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The tight junction protein ZO-1 is known to link the trans-
membrane proteins occludin, claudins, and JAMs tomany cyto-
plasmic proteins and the actin cytoskeleton. Although specific
roles for ZO-1 at the tight junction are unknown, it is widely
assumed that ZO-1, together with its homologs ZO-2 and ZO-3,
serves as a platform to scaffold various transmembrane and
cytoplasmic tight junction proteins. Thus the manner in which
the zonula occludens (ZO) proteins multimerize has implica-
tions for the protein networks they can coordinate. The purpose
of our studywas to determinewhether ZO-1 forms homodimers
and to determine the protein interaction region. Using laser
light scattering and analytical centrifugation, we show that pro-
tein sequences corresponding to the NH2-terminal half of ZO-1
form stable homodimerswith a submicromolar equilibriumdis-
sociation constant. Analysis of themolecular weight of different
truncated forms of ZO-1 revealed that the second PDZ domain
is both necessary and sufficient for dimerization. This interac-
tion does not use the -finger motif described for other PDZ
dimers. Furthermore, ZO-1 does not dimerize via an Src homol-
ogy 3 to Guk domain interaction as was demonstrated previ-
ously for MAGUKs, like PSD-95. Results from immunoprecipi-
tation experiments with polarized Madin-Darby canine kidney
epithelial cells stably transfected with full-length GFP-ZO-1
indicate that a substantial portion of ZO-1 forms homodimers
in vivo. As described previously, ZO-1 also forms heterodimers
with ZO-2 and ZO-3. We conclude that the dimerization of ZO
proteins is unlike that of otherMAGUKs and that the previously
unrecognized ZO-1 homodimers may allow formation of pro-
tein networks distinct from those of heterodimers with ZO-2
and ZO-3.
The tight junction (TJ)2 is the apical-most element of the
junctional complex in epithelial and endothelial cells. This
complex includes the TJ, adherens junctions, desmosomes, and
gap junctions. The TJ forms a major barrier to paracellular
movement of substances preserving unique chemical composi-
tion of apical and basolateral fluid compartments on opposite
sides of the epithelial cell layer and coordinates transmembrane
signaling (1, 2). The TJ is known to contain at least four classes
of transmembrane proteins and 30 cytoplasmic signaling,
scaffolding, and cytoskeletal proteins (3). To understand how
the barrier and signals are coordinated, more information is
required on the specific molecular interactions of TJ proteins
and specifically the proteins that coordinate interaction among
transmembrane and cytosolic proteins.
Peripheralmembraneproteins of the tight junction are believed
to be highly organized within a complicated network intercon-
necting cytoskeleton with transmembrane proteins. The three
homologous zonula occludens (ZO) MAGUK proteins (ZO-1,
ZO-2, and ZO-3) are among the best characterized peripheral
membrane proteins of the tight junction. They are composed of
three PDZ domains, an SH3-GUK unit, and an actin-binding
region; these proteins are believed to cluster different components
of tight junctions together through the direct binding to specific
domains and/or regions (3). Each has multiple known binding
partners; someare shared amongall three, such as binding to actin
and claudins, whereas others are unique, such as binding of
E4-ORF1 protein from type 9 adenovirus to ZO-2 (4). In tissues
lacking tight junctions, ZO proteins are localized to adherence
junction where they are presumed to interact with cadherin-cate-
nin complexes. Furthermore, ZO-1 was shown to bind many dif-
ferent connexins, structural components of gap junction, in a
number of reports (5–7).
Much efforts has been made to define the function of ZO
proteins, for example through exogenous expression of trun-
cated ZO-1 (3, 8, 9) and ZO-3 (10). A high degree of sequence
conservation between ZO proteins suggests that these proteins
may have a significant functional redundancy, making it diffi-
cult to elucidate their function. Strong evidence that ZO pro-
teins are indeed functionally redundant came from a recent
report demonstrating that in ZO-1-deficient cells, cytoplasmic
ZO-2 was recruited into tight junctions to compensate for
the loss of ZO-1 (11). ZO proteins are known to hetero-
oligomerize via their second PDZ domains. ZO-1 binds to
both ZO-2 and ZO-3, whereas ZO-2 and ZO-3 do not bind
each other (12). Because no endogenous ZO-1 from MDCK
cells was detected in immunoprecipitates of transiently
transfected human ZO-1, it was concluded that ZO-1 does
not form homo-oligomers (3). Hence, ZO proteins are
thought to exist exclusively as ZO-1/ZO-2 and ZO-1/ZO-3
heterodimers (12). Determining whether homodimers exist
is critical for understanding the complexity of protein net-
works that ZO proteins could create.
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In this work we demonstrate that, contrary to the previous
beliefs, ZO-1 forms a stable dimer via its second PDZ domain
and partially characterizes biophysical properties of the dimer.
We also show that significant amounts of ZO-1 in MDCK cells
exist as a homodimer.
EXPERIMENTAL PROCEDURES
Antibodies and Affinity Media—Mouse monoclonal anti-
bodies were purchased from Molecular Probes Inc. (Eugene,
OR). R40.76 antibodywas obtained fromBruce Stevenson (Salk
Institute, La Jolla, CA). All other antibodies and goat anti-rat
IgG immobilized on Sepharose 4Bwere purchased fromZymed
Laboratories Inc. Protein G-Sepharose was purchased fromGE
Healthcare.
Molecular Cloning—A NotI-XhoI fragment of plasmid
pSKZO-1 encoding about 1000 amino acid residues of ZO-1
was cloned into the pFastBacHTa vector. The resulting plasmid
was digested with NheI and HindIII and ligated by PCR with a
fragment of ZO-1 (720 bp) amplified with primers AATCAT
AAG GAG GTA GAA CGA GGC and TTT AA GCT TCT
AATCCGCCTTTCCCTCGGAAACCC to introduce a stop
codon after amino acid 806. To modify the NH2 terminus, the
construct was digested with NotI and KasI and ligated with
annealed oligonucleotides GCG CCA TGT CCG CCA GAG
CTG C and GGC CGC AGC TCT GGC GGA CAT G. The
resulting construct encodes amino acids 1–806 of humanZO-1
with anNH2-terminalHis6 tag.Other constructs were obtained
by similar procedures (details are available upon request).
These constructs and their amino acid sequence ranges are pre-
sented in Fig. 4. GFP-ZO-1was obtained by subcloning of ZO-1
into pEGFP-C1 vector, followed by subcloning of GFP-ZO-1
into pIRES vector.
Expression andPurification of RecombinantZO-1 Fragments—
Recombinant bacmids and baculoviruses were obtained using
Bac-to-Bac kit (Invitrogen). High Five cells were infected at a
multiplicity of infection of 3–5, harvested 48–60 h after infec-
tion, and kept frozen at 80 °C. Cell pellets were thawed in 6
volumes of lysis buffer (20 mM Tris-Cl, pH 8, 150–500 mM
NaCl, 10% glycerol, 0.8% Igepal CA-630, 12.5 mM imidazole, 5
mM 2-mercaptoethanol, and CompleteTM protease inhibitor
mixture (Roche Applied Science)), homogenized in a Dounce
homogenizer, and centrifuged for 10min at 20,000 g. Protein
was purified from the supernatant using EZviewTM Red His-
Select HC nickel affinity gel from Sigma and eluted into PBS
containing 5 mM -mercaptoethanol and 125 mM of imidazole.
MDCK Cell Culture, Transfection, and Stable Clone Selec-
tion—MDCK cells were cultivated in DMEM containing 10%
fetal bovine serum using 25-cm2 tissue culture flasks or 6-well
plates. Cells in 6-well plates were transfected with 3 g of GFP-
ZO-1 plasmid and 5 g of Cellfectin (Invitrogen) according to
the manufacturer’s instructions. Transfected cells were culti-
vated in media containing 0.8 mg/ml G-418, and cell clones
were isolated with cloning rings.
Immunoprecipitation and Immunoblotting—MDCK cells
grown on 50-cm2 Petri dishes were washed twice with PBS and
lysed in 0.6 ml of RIPA buffer (20 mM Tris-Cl, 150 mM NaCl, 5
mM 2-mercaptoethanol, 1% Triton X-100, 0.5% sodium deoxy-
cholate, and 0.1% SDS). The lysate was clarified by centrifuga-
tion at 15,000  g for 10 min and added to 30 l of protein G
beads preloaded with 5 g of antibodies. Beads were incubated
with the lysates for 2 h, washed five times with PBS containing
0.2% of Triton X-100, and boiled for 5 min in 100 l of electro-
phoresis sample buffer to elute boundproteins. Protein samples
were resolved on 4–12% gradient polyacrylamide gels (Invitro-
gen) and transferred onto nitrocellulose membranes. Mem-
branes were blocked in PBS containing 5% nonfat dry milk,
incubated with primary and fluorophore-labeled secondary
antibodies, and scanned with an Odyssey infrared imaging sys-
tem (LI-COR Biosciences, Lincoln, NE).
Analytical Centrifugation—Sedimentation equilibrium experi-
ments were performed with a Beckman Optima XL-A analytical
centrifuge. Partial specific volume of NZO-1 was estimated to
be 0.727 using SEDNTERP software. NZO-1 at 2–6 M was
analyzed in PBS containing 1mMof 2-mercaptoethanol at 20 °C
at speeds ranging between 6,000 and 20,000 rpm. Samples were
spun in a 6-channel 12-mm external fill equilibrium center-
piece in an An-60 Ti rotor. Scans (280 nm) were collected at
equilibrium in radial step mode with 0.001-cm steps and
5-point averaging. Data fitting was performed with one-com-
ponent or monomer-dimer equilibrium models using XL-A/
XL-I data analysis software (Beckman Instruments, Rockville,
MD).
Size Exclusion Chromatography with Multiangle Light Scat-
tering (SEC-MALS)—SEC-MALS experiments were performed
with anAkta FPLC (GEHealthcare) coupled to aWyattDAWN
EOS light scattering instrument, Wyatt Optilab refractometer,
andWyatt dynamic light scatteringmodule (Wyatt Technology
Corp., Santa Barbara, CA). For chromatographic separations, a
Superose 6 HR 10/30 column (GE Healthcare) equilibrated
with phosphate-buffered saline containing 5 mM 2-mercapto-
ethanolwas used at an eluent flow rate of 0.5ml/min.Molecular
weight calculations were made by ASTRA software using a
dn/dc value of 0.19 ml/g.
RESULTS
The NH2-terminal Half of ZO-1 Forms a Dimer in Solu-
tion—The protein corresponding to the NH2-terminal half of
ZO-1 (NZO-1, amino-acids 1–888) comprising three PDZ
FIGURE 1. Evidence for oligomerization of NZO-1. NZO-1, expressed in
insect cells and purified over Ni2-Sepharose, shows a single band of the
expected molecular weight with no major impurities (A). Gel filtration profile
suggests that NZO-1 may form a stable oligomer in solution (B).
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domains, an SH3 domain, a GuK domain, and an acidic domain
was purified to homogeneity from baculovirus-infected cells.
NZO-1 resolves as a 100-kDa band on polyacrylamide gel in the
presence of SDS (predicted molecular mass of NZO-1 is 102.7
kDa), showing no significant impurities (Fig. 1A). Size exclusion
chromatography revealed that NZO-1 elutes as a single peak
with an apparent molecular mass of 400 kDa, suggesting that
NZO-1 may form a stable oligomer or be very highly asymmet-
ric (Fig. 1B). Because size exclusion chromatography data are
dependent on the shape of the protein, the determination of the
exact molecular weight of the protein is difficult. To character-
ize the oligomeric state of NZO-1 in solution, we performed
size exclusion chromatography with on-line detection of light
scattering (LS) and refractive index (RI) signals, because this
approach allows an accurate measurement of the molecular
weight of the protein independently of its shape and/or amino
acid composition (13). Representative chromatographic pro-
files of NZO-1 obtained from LS and RI detectors are shown in
Fig. 2A. The molecular mass of the NZO-1 calculated from LS
and RI data was found to be 209 kDa indicating that NZO-1 is a
dimer. The molecular mass is independent of the elution vol-
ume (Fig. 2B) indicating the absence of significant amounts of
monomer and higher order oligomers under these conditions.
In an attempt to determine theKd
value of the dimer, the NZO-1 was
further characterized by analytical
centrifugation. In two independent
experiments, the single ideal species
fit of sedimentation equilibrium
data returned values close to 200
kDa indicating the predominance of
a dimer in solution. The analysis
of sedimentation equilibrium data
shows that good fits can be obtained
using amonomer-dimermodel (Fig.
3). However, because comparable
fits were obtained with a single spe-
cies model using the theoretical
molecular weight of the dimer (not
shown), we concluded that monomer concentrations are suffi-
ciently low that they cannot be determined accurately. This
precluded the determination of Kd values of monomer-dimer
equilibrium, still allowing us a theoretic analysis of simulated
binding isoterms, which suggested that the Kd must be below
0.7 M.
Identification of the Dimerization Domain—To define which
part ofNZO-1 is responsible for dimerization, we purified trun-
cated forms of NZO-1 using the insect cell/baculovirus expres-
sion system, andwe investigated their oligomerization status by
SEC-MALS. We created a truncated form lacking the seven
NH2-terminal amino acid residues of ZO-1 because another
MAGUK, hDlg, was reported to oligomerize via their NH2 ter-
mini (14). Other constructs lacking different domains are
shown on Fig. 4A. All constructs could be expressed and puri-
fied to apparent homogeneity (Fig. 4B). Molecular masses of all
proteins determined from the positions of visualized bands on
denaturing SDS-polyacrylamide gels are close to the corre-
sponding theoretical values except for PDZ2I2 (amino acids
183–349), which has an apparentmolecularmass 10 kDahigher
than predicted.
All purified truncation forms of ZO-1were subjected to SEC-
MALS in order to determine their molecular weight. Similarly
to NZO-1, all investigated proteins eluted as single peaks with
little or no dependence of calculated molecular weight on elu-
tion volume (data not shown). The results of SEC-MALS exper-
iments are summarized in Table 1. Absolute molecular masses
of all truncated forms of ZO-1 except PDZ3-acidic (this con-
struct was found to be a monomer) are close to the theoretical
masses of corresponding dimers (Table 1). Because all con-
structs except PDZ3-acidic include the second PDZ domain,
these results clearly indicate that PDZ2 is necessary and suffi-
cient for dimerization.
Dimerization of ZO-1 in Vivo—Because ZO-1 was not previ-
ously thought to dimerize, we next sought to determine
whether dimers exist in vivo. We established stable lines of
MDCK cells expressing either GFP or GFP-tagged ZO-1. As
reported previously (15), the distribution of GFP-ZO-1 was
similar to endogenous ZO-1, both being found almost exclu-
sively in tight junctions (Fig. 5A). The localization of ZO-1 in
control cells expressing GFP remained unchanged (Fig. 5A).
Endogenous ZO-1 was immunoprecipitated from GFP and
FIGURE 2. NZO-1 is a dimer. A, refractive index (solid line) and light scattering (dashed line) profiles of NZO-1; B,
the dependence of calculated molecular weight on elution volume. The profiles appear displaced because the
detectors are positioned in series in the flow path.
FIGURE 3. Sedimentation equilibrium analysis of NZO-1. Sedimentation
equilibrium data for NZO-1 at 5 M are shown for 8000 () and 1100 rpm (E).
Fits corresponding to the monomer-dimer model are shown as solid lines.
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GFP-ZO-1 expressing cell lines using the R40.76 monoclonal
antibody (this antibody recognizes canine but not exogenous
human GFP-ZO-1). A significant fraction of GFP-ZO-1 was
found to co-immunoprecipitate with endogenous ZO-1, indi-
cating the presence of ZO-1 dimers or higher order oligomers
in vivo (Fig. 5B). In converse experiments, whenGFP-ZO-1was
immunoprecipitated with anti-GFP antibodies endogenous
ZO-1was also found to co-immunoprecipitatewithGFP-ZO-1.
No binding of GFP to ZO-1 was observed in control experi-
ments (Fig. 5B).
To understand howZO-1 is distributed among homo- and het-
ero-oligomers with ZO-2 and ZO-3, we performed a series of
repeated immunoprecipitations trying to completely deplete
either ZO-1, ZO-2, or ZO-3 fromMDCK cell lysates with subse-
quent quantification of the proteins in bound and unbound frac-
tions. The NH2-terminal part of ZO-1 (amino acids 1–888) and
the full-lengthZO-2expressed in insect cells were used as stand-
ards to perform quantitative immunoblotting (Fig. 6A); ZO-3
from insect cells could not be obtained in sufficient purity.
ZO-2 and ZO-3 were depleted from the MDCK cell lysate to
find out what fraction of ZO-1 is not bound to ZO-2 and ZO-3.
A representative experiment and quantification as shown in
Fig. 6B show that over 85% of ZO-2 and over 95% of ZO-3 could
be immunoprecipitated with antibodies directed against them.
Quantitative analysis of ZO-1 revealed that about 107 fmol
(50%) of solubilized ZO-1 is not bound to either ZO-2 or ZO-3
and remains in the supernatant. Accordingly, we found that
about 50% of ZO-1 is bound to ZO-2 and ZO-3.
Finally, we used MDCK cells stably expressing GFP-ZO-1 to
quantify the amount of ZO-2 and GFP-ZO-1 that co-precipi-
tate with endogenous ZO-1. Fig. 6C shows that endogenous
ZO-1 could be quantitatively precipitated from MDCK cells
stably expressing GFP-ZO-1. Immunoblotting with anti-GFP
antibodies (Fig. 6C) revealed that about 40% of GFP-ZO-1 co-
precipitated with endogenous ZO-1. Immunoblot with rabbit
antibodies recognizing both GFP-ZO-1 and endogenous ZO-1
allowed us quantify the amounts of these proteins. Endogenous
ZO-1 (arrowhead) and GFP-ZO-1 (arrow) were found to be
expressed at comparable levels (Fig. 6C). Analysis of the protein
sample obtained from R40.76 immunoprecipitates revealed
that it contains 90 fmol of endogenous ZO-1 and about 65 fmol
of GFP-ZO-1. Analysis with anti-ZO-2 antibodies revealed that
19 fmol of ZO-2 co-precipitated with endogenous ZO-1 (Fig.
6C) in MDCK cells stably expressing GFP-ZO-1 (Fig. 6C).
DISCUSSION
ZO-1was the first tight junction protein to be discovered and is
thought to be one of the major scaffolds at tight junctions. The
biochemical and biophysical proper-
ties of ZO-1 were poorly character-
ized so far, probably because of
the difficulties associated with the
expression of large constructs in bac-
teria. Using insect cells/baculovirus
expression system, we were able to
obtain milligram amounts of the
NH2-terminal part of ZO-1 (the basic
core structureZO-1shareswithother
MAGUKs likePSD-95anddisc large),
which permitted the first detailed
characterization of its biophysical
properties. Because of anomalous gel
filtration behavior ofNZO-1,we used
multiangle light scattering to charac-
terize its oligomeric state. Unexpect-
edly,NZO-1was found to exist exclu-
sively as a stable dimer. Analytical
centrifugationconfirmedthatNZO-1
FIGURE 4. Truncated ZO-1 constructs expressed in insect cells. A, different truncated mutants of NZO-1
designed for expression. B, Coomassie-stained polyacrylamide gel showing truncated ZO-1 proteins expressed
in baculovirus-infected insect cells and purified to apparent homogeneity with Ni2-Sepharose and used for
study of their oligomeric state.
TABLE 1
Identification of dimerization motif of ZO-1 by light scattering








NZO1 1–888 102.7 205.4 209 Dimer
acidic 1–806 93.8 187.6 185 Dimer
N7 8–806 92.9 185.8 183 Dimer
GuK 1–640 74.8 149.6 147 Dimer
PDZ1-3 1–502 58.8 117.6 126 Dimer
PDZ1-2I2a 1–300 38.9 77.8 78.9 Dimer
PDZ1-2 1–275 33.4 66.8 71.0 Dimer
PDZ1I1 178–806 74.2 148.4 145 Dimer
PDZ3-acidic 414–888 56.3 112.6 53.6 Monomer
PDZ2I2 183–349 30.3 60.6 70.8 Dimer
PDZ2 183–275 14.0 28.0 28.3 Dimer
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forms a dimer with a submicromolar equilibrium dissociation
constant. Such a low Kd value implies that NZO-1 would readily
form homodimers in vivo.
By analyzing the oligomerization status of various truncation
mutants of ZO-1, we could unambiguously identify PDZ2 as a
dimerization motif. The dimerization does not seem to occur
via the recognition of internal “-finger” by PDZ2 as in the case
of neuronal nitric-oxide synthase-syntrophin (16), because the
deletion of the regions flanking PDZ2 did not disrupt dimer
formation. Rather, PDZ2 itself is likely to create a specific
dimerization interface as reported for PDZ domains of Shank
(17) andGRIP1 (18). The SH3-GuK unit of ZO-1 does not seem
to contribute to oligomerization by domain swapping as sug-
gested previously (19), because a construct containing PDZ3,
SH3, GuK, and acidic domain was found to exist exclusively as
a monomer.
Because ZO-1/ZO-2 interaction was shown to involve the
second PDZ domains of ZO-1 and ZO-2 (3, 20), it appears that
second PDZ domains of all ZO proteins possess an intrinsic
ability to dimerize. This idea is supported by the fact that the
second PDZ domains of ZO proteins are very well conserved
(70% identity and 94% similarity betweenPDZ2of humanZO-1
and ZO-2). Noteworthy, previous reports suggest that various
deletion mutants of ZO-2 bound to ZO-1 only if co-expressed
in fibroblasts; no bindingwas detected using separately purified
proteins for in vitro binding assays (20). Based on our results,
this is most likely due to the inability of ZO-2 to disrupt pre-
formed dimers of ZO-1 and/or vice versa. In this regard, in vitro
binding assays with separately purified ZO proteins seem to be
less reliable compared with experiments utilizing co-expres-
sion of proteins in the same cell.
The previous report of Fanning et al. (3) suggests that ZO-1
does not form homo-oligomers in MDCK cells because tran-
siently transfected human ZO-1 and its deletion mutants did
not precipitate endogenous canine ZO-1. This conclusion dif-
fers from that of the current study. A possible explanation for
the previous failure to detect the ZO-1/ZO-1 interaction is that
low levels of transient transfection efficiency and/or the low
expression levels of transfected ZO-1 precluded the detection
of the binding. To overcome the problem of low transfection
rate and low expression levels, we cloned GFP-ZO-1 into the
pIRES vector that is designed to select cells with high expres-
sions of transgene polypeptides. Stably expressing GFP-ZO-1
correctly targets to the tight junction. Using R40.76 antibody to
precipitate endogenous ZO-1 and anti-GFP antibody to precip-
itate exogenous GFP-ZO-1, we could show that homodimers
(or homo-oligomers) of ZO-1 exist in vivo.
In another experiment we could precipitate about 85% of
ZO-2 and over 95% of ZO-3 from MDCK cell lysates. Even if
one assumes that the remaining 15% of ZO-2 (32 fmol) is
bound to ZO-1, about one-third of the total ZO-1 appears to be
free of ZO-2 or ZO-3. In addition, in contrast to ZO-2 and
FIGURE 5. Oligomerization of ZO-1 in vivo. A, the distribution of GFP-ZO-1 is similar to endogenous (endog.) ZO-1 localizing at tight junctions, whereas GFP
in control cells localizes to the cytoplasm (bar, 10 m). B, in cells expressing GFP-ZO-1 (left) or GFP alone (right), transgenic constructs were precipitated using
anti-GFP antibodies, whereas endogenous ZO-1 was precipitated using R40.76 antibody. IP, immunoprecipitate. Immunoblot analysis with anti-GFP antibod-
ies shows that GFP-ZO-1 but not GFP co-precipitates with endogenous ZO-1 (upper panel). Heavy and light chains of immunoglobulins are marked with
arrowheads. Lower panel shows that endogenous ZO-1 co-precipitates with GFP-ZO-1 but not GFP control.
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ZO-3, a substantial amount of ZO-1 is not soluble in RIPA
buffer and is therefore likely not to be in a complex with ZO-2
andZO-3.Wedonot have ultimate proof that ZO-1 is free from
ZO-2/ZO-3 and exists in a cell as a homodimer or homo-oli-
gomer. However, experiments with cell lines expressing GFP-
ZO-1 indicate that ZO-1/ZO-1 dimers are at least as abundant
as ZO-1/ZO-2 heterodimers. Given that purified recombinant
NZO-1 exists exclusively as a dimer with submicromolar Kd, it
is likely that ZO-1 free of ZO-2 and ZO-3 dimerizes in the cell
via its second PDZ domain.
The relative efficiencies of homo- or hetero-oligomeriza-
tions between all ZO proteins have yet to be determined, but it
is likely that the percentage of all kinds of homodimers and
heterodimers will be dependent on the relative level of expres-
sion of all ZO proteins. In this regard, it is interesting that the
expression profiles of ZO proteins differ from each other in
various tissues indicating that various types of mono- and het-
erodimers of ZO proteins may form in different tissues. For
example, ZO-3 is absent in ZO-1/ZO-2-positive endothelial
tight junctions (21), and the expression levels of ZO-1 andZO-2
show different patterns along the nephron (22). Furthermore, a
significant part of ZO-3 and especially of ZO-2 is localized to
the cytoplasm of highly polarized cells, whereas ZO-1 is local-
ized almost exclusively to the tight junction (Fig. 5A). This
implies that particular homo- and hetero-oligomers of ZO pro-
teins may also have differential subcellular distribution.
ZO-1 and other MAGUKs are implicated in scaffolding of
different proteins at plasma membranes through the direct
binding to PDZ, SH3, and GuK domains. To enhance cluster-
ing, MAGUKs oligomerize via different mechanisms. For
example, neuronal MAGUK PSD-95 was found to oligomerize
through palmitoylation of two NH2-terminal cysteines (23).
The clustering of K channels was found to be palmitoylation-
dependent, pointing to palmitoylation as a potential regulation
mechanism (23). ZO proteins, which are normally associated
with tight junction in epithelial cells, are unique among
MAGUKs in their ability to form highly stable dimers via the
second PDZ domain. It is likely that the dimerization is highly
important for the function of ZO proteins as molecular scaf-
folds, and our future studies will be aimed at understanding the
role of PDZ2-dependent dimerization for the function of ZO
proteins.
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